<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:psc="http://podlove.org/simple-chapters" xmlns:podcast="https://podcastindex.org/namespace/1.0"><channel><title><![CDATA[Excellence in Healthcare Delivery Across the Lung Cancer Continuum]]></title><description><![CDATA[<p>Season 1: Precision Oncology in NSCLC: HER2 Mutation and Guideline Target Therapies</p><p>In this seven-part podcast series, leading experts discuss the role of precision oncology in non-small cell lung cancer, with a focus on HER2 mutations and current guideline-based targeted treatment.</p>]]></description><link>https://gkc.go2.org/</link><generator>Riverside.fm (https://riverside.com)</generator><lastBuildDate>Wed, 04 Nov 2026 03:35:18 GMT</lastBuildDate><atom:link href="https://api.riverside.com/hosting/LAGyO3oL.rss" rel="self" type="application/rss+xml"/><author><![CDATA[GKC for Lung Cancer]]></author><pubDate>Mon, 02 Mar 2026 16:01:43 GMT</pubDate><copyright><![CDATA[2026 GKC for Lung Cancer]]></copyright><language><![CDATA[en]]></language><ttl>60</ttl><category><![CDATA[Non-Profit]]></category><category><![CDATA[Medicine]]></category><itunes:author>GKC for Lung Cancer</itunes:author><itunes:summary>&lt;p&gt;Season 1: Precision Oncology in NSCLC: HER2 Mutation and Guideline Target Therapies&lt;/p&gt;&lt;p&gt;In this seven-part podcast series, leading experts discuss the role of precision oncology in non-small cell lung cancer, with a focus on HER2 mutations and current guideline-based targeted treatment.&lt;/p&gt;</itunes:summary><itunes:type>episodic</itunes:type><itunes:owner><itunes:name>GKC for Lung Cancer</itunes:name><itunes:email>knowledge@go2.org</itunes:email></itunes:owner><itunes:explicit>no</itunes:explicit><itunes:category text="Business"><itunes:category text="Non-Profit"/></itunes:category><itunes:category text="Health &amp; Fitness"><itunes:category text="Medicine"/></itunes:category><itunes:image href="https://hosting-media.riverside.com/media/podcasts/f7ec891a-c99e-4b6d-b3f6-e6296347cd57/logos/4a52f956-4625-4997-8bd4-d6b0280c4141.png"/><item><title><![CDATA[S1E1: HER2 Series: Understanding NSCLC Histology and Oncogenesis of HER2 (ERBB2) Mutation in NSCLC]]></title><description><![CDATA[<p>In this episode, Dr. Andrew Ciupek interviews Dr. Courtney Granville about NSCLC histologic subtypes and HER2 alterations, including mutation, amplification, and overexpression, and how HER2-driven signaling pathways promote tumor growth and progression.</p><p>Note: this is a companion podcast to the continuing education course in the GO2 for Lung Cancer Global Knowledge Center.</p><p>Select the link below to go to the full continuing education course:</p><p><a href="https://gkc.go2.org/courses/histology_and_oncogensis_HER2" rel="noopener noreferrer nofollow">⁠Understanding NSCLC Histology and Oncogenesis of HER2 (ERBB2) Mutation in NSCLC</a></p>]]></description><guid isPermaLink="false">8ee0cc8a-d002-437e-97ed-8f1b4c2b7e70</guid><dc:creator><![CDATA[GKC for Lung Cancer]]></dc:creator><pubDate>Thu, 29 Oct 2026 22:03:11 GMT</pubDate><enclosure url="https://api.riverside.com/hosting-analytics/media/0950ea405e68c01430ef234c675c7b982d9221784e24c1fdc70022d3fabcc598/eyJlcGlzb2RlSWQiOiI4ZWUwY2M4YS1kMDAyLTQzN2UtOTdlZC04ZjFiNGMyYjdlNzAiLCJwb2RjYXN0SWQiOiJmN2VjODkxYS1jOTllLTRiNmQtYjNmNi1lNjI5NjM0N2NkNTciLCJhY2NvdW50SWQiOiI2NjZiMzA2NDY3OTE1M2EzMGI2M2I4NTciLCJwYXRoIjoibWVkaWEvY2xpcHMvNmFkN2NiZDZmNzgzZjM0M2RmNTZkM2E1L2dvMi1mb3ItbHVuZy1jYW5jZXJzLXN0dWRpby0yMDI2LTEwLTIwX18yMC0xNS0xOC5tcDMifQ==.mp3" length="52753181" type="audio/mpeg"/><podcast:transcript url="https://hosting-media.riverside.com/media/podcasts/f7ec891a-c99e-4b6d-b3f6-e6296347cd57/episodes/8ee0cc8a-d002-437e-97ed-8f1b4c2b7e70/transcripts.txt" type="text/plain"/><itunes:summary>&lt;p&gt;In this episode, Dr. Andrew Ciupek interviews Dr. Courtney Granville about NSCLC histologic subtypes and HER2 alterations, including mutation, amplification, and overexpression, and how HER2-driven signaling pathways promote tumor growth and progression.&lt;/p&gt;&lt;p&gt;Note: this is a companion podcast to the continuing education course in the GO2 for Lung Cancer Global Knowledge Center.&lt;/p&gt;&lt;p&gt;Select the link below to go to the full continuing education course:&lt;/p&gt;&lt;p&gt;&lt;a href=&quot;https://gkc.go2.org/courses/histology_and_oncogensis_HER2&quot; rel=&quot;noopener noreferrer nofollow&quot;&gt;⁠Understanding NSCLC Histology and Oncogenesis of HER2 (ERBB2) Mutation in NSCLC&lt;/a&gt;&lt;/p&gt;</itunes:summary><itunes:explicit>no</itunes:explicit><itunes:duration>00:27:29</itunes:duration><itunes:image href="https://hosting-media.riverside.com/media/podcasts/f7ec891a-c99e-4b6d-b3f6-e6296347cd57/logos/4a52f956-4625-4997-8bd4-d6b0280c4141.png"/><itunes:season>1</itunes:season><itunes:episode>1</itunes:episode><itunes:title>S1E1: HER2 Series: Understanding NSCLC Histology and Oncogenesis of HER2 (ERBB2) Mutation in NSCLC</itunes:title><itunes:episodeType>full</itunes:episodeType></item></channel></rss>